First Patient Enrolls for Primary Sclerosing Cholangitis Proof-of-Concept Study
DarkoStojanovic / Pixabay

First Patient Enrolls for Primary Sclerosing Cholangitis Proof-of-Concept Study

According to a story from BioSpace, the biopharmaceutical company Immunic, Inc. has announced that the first patient has signed up for its proof-of-concept clinical study. This study is intended to…

Continue Reading First Patient Enrolls for Primary Sclerosing Cholangitis Proof-of-Concept Study
Patient With Long Term Untreated Lyme Disease is Raising Money for Specialty Treatment in the US
Elionas / Pixabay

Patient With Long Term Untreated Lyme Disease is Raising Money for Specialty Treatment in the US

According to a story from Express Digest, 22 year old Steph Todd first started experiencing symptoms of Lyme disease in 2015, when she presented with flu-like symptoms and a circular…

Continue Reading Patient With Long Term Untreated Lyme Disease is Raising Money for Specialty Treatment in the US
If You Have IBD, You Have Access to Employee Bathrooms. If You’re an Employee, You Should Know That.
Source: www.pixabay.com

If You Have IBD, You Have Access to Employee Bathrooms. If You’re an Employee, You Should Know That.

In a story reported in the Boston Globe, Stephen Marcus, as a person with Crohn’s disease, knows the laws surrounding bathroom policies from public franchises. He worked as a lawyer…

Continue Reading If You Have IBD, You Have Access to Employee Bathrooms. If You’re an Employee, You Should Know That.

Come On Pharma: It’s Not That Much of a Sacrifice to Study One Rare Disease Pro-Bono

At the heart of rare disease treatments is research. Currently, 95% of all rare diseases still have no approved therapies. Although there has been an increased focus on rare diseases…

Continue Reading Come On Pharma: It’s Not That Much of a Sacrifice to Study One Rare Disease Pro-Bono

The FDA Will Allow the Most Expensive Therapy in the World to Remain on the Market

The headline in a recent Washington Post article declared that the FDA claimed Novartis, through its newly-acquired company AveXis, manipulated data in an application for a gene therapy drug. These…

Continue Reading The FDA Will Allow the Most Expensive Therapy in the World to Remain on the Market
Close Menu